Darotropium (bromide)

• Description :

  Darotropium bromide (GSK233705), a long-acting muscarinic antagonist and an inhaled anticholinergic, can be used for the research of chronic obstructive pulmonary disease (COPD) [1][2].

• Product Name Alternative :

  GSK233705

• UNSPSC :

  12352005

• Target :

  MAChR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/darotropium-bromide.html

• Smiles :

  [H][C@]1(CC(C2=CC=CC=C2)(C#N)C3=CC=CC=C3)C[C@]4([H])[N+](C)(C)[C@@]([H])(CC4)C1.[Br-]

• Molecular Formula :

  C24H29BrN2

• Molecular Weight :

  425.40

• References & Citations :

  [1]Jutta Beier, et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis. 2012:7:153-64.|[2]Eric Bateman, et al. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clin Respir J. 2012 Oct;6 (4) :248-57.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [850607-58-8]